Get the Stockscreener App
9.47
12.07%
1.02
After Hours:
9.50
0.03
+0.32%
Upstream Bio Inc stock is traded at $9.47, with a volume of 672.98K.
It is up +12.07% in the last 24 hours and up +22.35% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$8.45
Open:
$8.68
24h Volume:
672.98K
Relative Volume:
0.54
Market Cap:
$511.75M
Revenue:
$2.80M
Net Income/Loss:
$-122.23M
P/E Ratio:
-4.1462
EPS:
-2.284
Net Cash Flow:
$-46.53M
1W Performance:
+9.29%
1M Performance:
+22.35%
6M Performance:
-41.94%
1Y Performance:
+24.12%
1-Day Range:
$8.67
$9.57
1-Week Range:
$8.12
$9.57
52-Week Range:
$5.14
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
9.47 | 456.63M | 2.80M | -122.23M | -46.53M | -2.284 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio (NASDAQ:UPB) Trading Up 11.2%What's Next? - MarketBeat
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Aug EndMonth: What is the next catalyst for Upstream Bio IncMarket Trend Report & Stock Timing and Entry Methods - baoquankhu1.vn
Upstream Bio Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
UPB | Upstream Bio, Inc. Common Insider Trading - Quiver Quantitative
Upstream Bio CFO Gray sells $7915 in shares - Investing.com
Upstream Bio CFO Gray sells $7915 in shares By Investing.com - Investing.com South Africa
Upstream Bio CEO Makes Notable Move With Fresh Stock Sale - TipRanks
Upstream Bio (UPB) CFO executes automatic share sale to cover RSU taxes - Stock Titan
Upstream Bio (UPB) CMO auto-sells 894 shares to cover RSU taxes - Stock Titan
Tax-related sale: Upstream Bio (UPB) CEO automatically sells 2,093 shares - Stock Titan
Tax-withholding share sale by Upstream Bio (UPB) General Counsel disclosed - Stock Titan
Tax-related stock sale by Upstream Bio (UPB) chief business officer - Stock Titan
Risk Recap: Whats next for Upstream Bio Inc stockM&A Rumor & Short-Term Swing Trade Alerts - baoquankhu1.vn
Integral Health Asset Management LLC Acquires New Stake in Upstream Bio, Inc. $UPB - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Trading 14.4% HigherShould You Buy? - MarketBeat
UPB: Phase II data support quarterly dosing for verekitug, with phase III and COPD programs advancing - TradingView
UPB: Verekitug's quarterly dosing shows robust efficacy, with phase 3 and COPD programs advancing - TradingView
Upstream Bio, Inc. CEO joins Leerink Partners fireside chat at global healthcare conference - Traders Union
Dip Buying: Is Upstream Bio Inc forming a breakout pattern2025 Stock Rankings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Upstream Bio's selloff may be 'overdone,' but analyst highlights asthma drug's competitive edge concerns - MSN
Aug Sectors: Can Upstream Bio Inc deliver consistent dividendsJuly 2025 Outlook & Community Verified Watchlist Alerts - baoquankhu1.vn
Lifesci Capital Forecasts Upstream Bio Q2 Earnings - MarketBeat
Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Price Target at $45.25 - Defense World
Why Did UPB Stock Plunge 40% Today? - Stocktwits
RSI Check: Can Upstream Bio Inc outperform in the next rallyWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
UPB: Verekitug shows best-in-class efficacy and safety, advancing to phase 3 with quarterly dosing - TradingView
CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts - Traders Union
Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio presents additional Phase 2 data for verekitug - Investing.com South Africa
Upstream Bio presents additional Phase 2 data for verekitug By Investing.com - Investing.com Canada
Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026 - Traders Union
Upstream Bio says primary endpoint showed reduction of -1.95 in nasal polyp score - marketscreener.com
Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score - TradingView
Upstream Bio Presents Additional Analyses from the Phase 2 - GlobeNewswire
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 505% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Upstream Bio to present verekitug CRSwNP trial data at AAAAI By Investing.com - Investing.com Australia
Upstream Bio to present verekitug CRSwNP trial data at AAAAI - Investing.com
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - Bitget
UPB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Latest UPB NewsUpstream Bio Reports Fourth Quarter and Full... - Stock Titan
Upstream Bio to Participate in Investor Conferences in March 2026 - geneonline.com
Peering Into Upstream Bio Inc's Recent Short Interest - Benzinga
Upstream Bio announces participation in major healthcare conferences - Traders Union
Upstream Bio to Participate in Upcoming March Investor Conferences - GlobeNewswire
Insider Trends: Is Upstream Bio Inc a defensive stockTrade Entry Summary & Community Driven Trade Alerts - baoquankhu1.vn
Can Upstream Bio Inc. ride the EV waveJuly 2025 Rallies & Expert Approved Momentum Ideas - mfd.ru
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):